Sionna Therapeutics Inc (SION) Stock Price, Quote & News

Company Profile

Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 819 2020

Website: www.sionnatx.com

Address:

21 Hickory Drive, Suite 500, Waltham, United States

CH_Expat Jul. 24 at 4:50 PM

$SION @Kingjake26 Look here. Dead board. 45 watchers. Look at the MC, look at the IO. I am not invested because I missed it in the low 30s.

1 · Reply

QuietLattice Jul. 24 at 1:06 PM

$SION spiked to ~51 Fri then sold back into the mid-40s. post-spike fade — watching if mid-40s stick

0 · Reply

Soraya123 Jul. 24 at 11:33 AM

$SION Unlike many small biotechs with a single lead asset!! SION has several drug candidates in clinical development, including correctors, potentiators, and CFTR stabilizers. This diversification may reduce single-program risk.

0 · Reply

howardlindzon Jul. 19 at 12:59 PM

$SION $ 2 billion just 60 followers - a trend woth literally NO friends

1 · Reply

Trainguy1 Jul. 17 at 8:31 PM

$SION Are we seeing foreshadowing of what’s to happen next week? I wonder if SION will readout top line results from one or two trials?

0 · Reply

laaarsas Jul. 17 at 4:38 PM

$SION FUCK I should have loaded up more in the mid 30s I hate my life.

1 · Reply

STRelativeStrength Jul. 17 at 3:35 PM

$SION undiscovered breakout with 62 watchers

0 · Reply

ajmrtxl Jul. 16 at 1:05 PM

$SION 's latest squeeze play

0 · Reply

laaarsas Jun. 9 at 5:58 AM

$SION Where is next support level?

0 · Reply

laaarsas Jun. 5 at 12:01 PM

$SION No activity here dispite huge gains in last year. What share price do you expect if data is good in Q3?

0 · Reply

Sionna Therapeutics rises 9.2%

Jun 10, 2026, 10:00 AM EDT - 6 weeks ago

Sionna Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 3, 2026, 12:15 PM EDT - 7 weeks ago

Sionna Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

May 27, 2026, 8:00 AM EDT - 2 months ago

Sionna Therapeutics to Participate in Upcoming June 2026 Investor Conferences

May 20, 2026, 2:05 PM EDT - 2 months ago

Sionna Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026

2026-05-20T14:50:10.000Z - 2 months ago

Sionna Therapeutics downgraded at Freedom Broker with unchanged target

2026-05-20T14:46:03.000Z - 2 months ago

Sionna Therapeutics downgraded to Hold from Buy at Freedom Broker

2026-05-18T10:46:33.000Z - 2 months ago

Sionna Therapeutics price target raised to $55 from $44 at Stifel

May 13, 2026, 8:00 AM EDT - 2 months ago

Sionna Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

2026-05-12T12:31:39.000Z - 2 months ago

Sionna Therapeutics reports Q1 EPS (60c), consensus (50c)

May 12, 2026, 7:00 AM EDT - 2 months ago

Sionna Therapeutics Reports First Quarter 2026 Financial Results

May 12, 2026, 7:00 AM EDT - 2 months ago

Sionna Therapeutics Earnings release: Q1 2026

May 12, 2026, 7:00 AM EDT - 2 months ago

Sionna Therapeutics Quarterly report: Q1 2026

May 12, 2026, 7:00 AM EDT - 2 months ago

Sionna Therapeutics Slides: Corporate presentation

2026-05-04T20:21:26.000Z - 2 months ago

Sionna Therapeutics initiated with an Outperform at Wedbush

2026-04-28T10:20:16.000Z - 3 months ago

Sionna Therapeutics price target raised to $63 from $52 at JonesResearch

Apr 27, 2026, 8:00 AM EDT - 3 months ago

Sionna Therapeutics Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 3 months ago

Sionna Therapeutics Proxy statement: Proxy filing

Apr 27, 2026, 7:00 AM EDT - 3 months ago

Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis

Apr 7, 2026, 7:00 AM EDT - 3 months ago

Sionna Therapeutics to Participate in the Raymond James 2026 Biotech Innovation Symposium

Mar 10, 2026, 1:40 PM EDT - 4 months ago

Sionna Therapeutics Transcript: Leerink Global Healthcare Conference 2026

2026-03-03T12:19:45.000Z - 5 months ago

Sionna Therapeutics price target raised to $50 from $45 at Guggenheim

Mar 2, 2026, 2:30 PM EST - 5 months ago

Sionna Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

2026-03-02T13:34:52.000Z - 5 months ago

Sionna Therapeutics files automatic mixed securities shelf

2026-03-02T13:28:22.000Z - 5 months ago

Sionna Therapeutics files automatic mixed securities shelf

2026-03-02T13:23:17.000Z - 5 months ago

Sionna Therapeutics files automatic mixed securities shelf

2026-03-02T12:09:18.000Z - 5 months ago

Sionna Therapeutics reports Q4 EPS (46c), consensus (55c)

Mar 2, 2026, 7:00 AM EST - 5 months ago

Sionna Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

Mar 2, 2026, 7:00 AM EST - 5 months ago

Sionna Therapeutics Annual report: Q4 2025

Mar 2, 2026, 7:00 AM EST - 5 months ago

Sionna Therapeutics Earnings release: Q4 2025

Mar 2, 2026, 7:00 AM EST - 5 months ago

Sionna Therapeutics Slides: Corporate presentation

2026-02-24T09:40:13.000Z - 5 months ago

Sionna Therapeutics initiated with an Outperform at Citizens

Feb 23, 2026, 8:00 AM EST - 5 months ago

Sionna Therapeutics to Participate in Upcoming March 2026 Investor Conferences

Feb 11, 2026, 2:00 PM EST - 5 months ago

Sionna Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 4, 2026, 7:00 AM EST - 6 months ago

Sionna Therapeutics to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Jan 13, 2026, 12:45 PM EST - 6 months ago

Sionna Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

2026-01-08T12:00:46.000Z - 7 months ago

Sionna Therapeutics price target raised to $58 from $50 at BTIG

VRTX

2026-01-07T12:10:27.000Z - 7 months ago

Sionna Therapeutics price target raised to $58 from $50 at BTIG

Jan 7, 2026, 7:00 AM EST - 7 months ago

Sionna Therapeutics Slides: Corporate presentation

Jan 5, 2026, 7:00 AM EST - 7 months ago

Sionna Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

2025-12-23T13:50:31.000Z - 7 months ago

Sionna Therapeutics initiated with an Outperform at LifeSci Capital

Dec 4, 2025, 9:45 AM EST - 8 months ago

Sionna Therapeutics Transcript: Citi Annual Global Healthcare Conference 2025

Dec 3, 2025, 12:30 PM EST - 8 months ago

Sionna Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Nov 24, 2025, 7:00 AM EST - 8 months ago

Sionna Therapeutics to Participate in Upcoming December Investor Conferences

Nov 12, 2025, 8:00 AM EST - 9 months ago

Sionna Therapeutics Transcript: Stifel 2025 Healthcare Conference

Nov 11, 2025, 8:30 AM EST - 9 months ago

Sionna Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 5, 2025, 7:00 AM EST - 9 months ago

Sionna Therapeutics Reports Third Quarter 2025 Financial Results

Nov 5, 2025, 7:00 AM EST - 9 months ago

Sionna Therapeutics Quarterly report: Q3 2025

Nov 5, 2025, 7:00 AM EST - 9 months ago

Sionna Therapeutics Earnings release: Q3 2025

Nov 4, 2025, 8:00 AM EST - 9 months ago

Sionna Therapeutics to Participate in Upcoming November Investor Conferences

Oct 24, 2025, 1:15 PM EDT - 9 months ago

Sionna Therapeutics Announces Presentation of SION-719 and SION-451 Phase 1 Data and Poster of New Preclinical Data on the Impact of NBD1 Stabilizers on F508del-CFTR Half-Life at the 2025 North American Cystic Fibrosis Conference

Oct 21, 2025, 7:00 AM EDT - 9 months ago

Sionna Therapeutics Announces Initiation of PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, When Added to Standard of Care in Participants with Cystic Fibrosis

Oct 20, 2025, 6:00 PM EDT - 9 months ago

Sionna Therapeutics Slides: Corporate Presentation

Oct 1, 2025, 4:05 PM EDT - 10 months ago

Sionna Therapeutics to Present Data at the 2025 North American Cystic Fibrosis Conference

Sep 8, 2025, 8:00 AM EDT - 11 months ago

Sionna Therapeutics Appoints Caroline Stark Beer as Chief Business Officer

Sep 8, 2025, 7:00 AM EDT - 11 months ago

Sionna Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 3, 2025, 1:35 PM EDT - 11 months ago

Sionna Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Aug 27, 2025, 7:00 AM EDT - 11 months ago

Sionna Therapeutics to Participate in Upcoming September Investor Conferences

Aug 25, 2025, 7:00 AM EDT - 11 months ago

Sionna Therapeutics Announces First Subjects Dosed in Phase 1 Trial Evaluating NBD1 Stabilizer, SION-451, in Proprietary Dual Combinations in Development for the Treatment of Cystic Fibrosis

Aug 11, 2025, 7:00 AM EDT - 1 year ago

Sionna Therapeutics Reports Second Quarter 2025 Financial Results

Aug 11, 2025, 7:00 AM EDT - 1 year ago

Sionna Therapeutics Quarterly report: Q2 2025

Aug 11, 2025, 7:00 AM EDT - 1 year ago

Sionna Therapeutics Earnings release: Q2 2025

Jun 11, 2025, 8:00 AM EDT - 1 year ago

Sionna Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025

Jun 6, 2025, 11:00 AM EDT - 1 year ago

Sionna Therapeutics Announces Presentation of Preclinical Data that Demonstrate Proprietary Dual Combination Therapies Enable Full CFTR Correction in CFHBE Model

Jun 4, 2025, 8:00 AM EDT - 1 year ago

Sionna Therapeutics Transcript: Study Update

Jun 4, 2025, 8:00 AM EDT - 1 year ago

Sionna Therapeutics Press release: Study Update

Jun 4, 2025, 8:00 AM EDT - 1 year ago

Sionna Therapeutics Slides: Study Update

Jun 4, 2025, 7:00 AM EDT - 1 year ago

Sionna Therapeutics Announces Positive Phase 1 Data for NBD1 Stabilizers SION-719 and SION-451 and Advances Both Programs in Clinical Development for Cystic Fibrosis

Jun 3, 2025, 7:00 AM EDT - 1 year ago

Sionna Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

May 22, 2025, 7:00 AM EDT - 1 year ago

Sionna Therapeutics to Present Preclinical Data During Oral Session at the 48th European Cystic Fibrosis Conference

May 12, 2025, 7:00 AM EDT - 1 year ago

Sionna Therapeutics Reports First Quarter 2025 Financial Results

May 12, 2025, 7:00 AM EDT - 1 year ago

Sionna Therapeutics Quarterly report: Q1 2025

May 12, 2025, 7:00 AM EDT - 1 year ago

Sionna Therapeutics Earnings release: Q1 2025

May 7, 2025, 12:30 PM EDT - 1 year ago

Sionna Therapeutics Transcript: The Citizens JMP Life Sciences Conference 2025

Apr 30, 2025, 7:00 AM EDT - 1 year ago

Sionna Therapeutics to Present at The Citizens Life Sciences Conference 2025

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Sionna Therapeutics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Sionna Therapeutics Proxy statement: Proxy Filing

Mar 20, 2025, 8:00 AM EDT - 1 year ago

Sionna Therapeutics Earnings release: Q4 2024

Mar 20, 2025, 8:00 AM EDT - 1 year ago

Sionna Therapeutics Annual report: Q4 2024

Mar 20, 2025, 7:00 AM EDT - 1 year ago

Sionna Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 3, 2025, 2:00 PM EST - 1 year ago

Sionna Therapeutics Transcript: 45th Annual TD Cowen Health Care Conference

Feb 24, 2025, 8:00 AM EST - 1 year ago

Sionna Therapeutics to Present at the 45th Annual TD Cowen Health Care Conference

Feb 10, 2025, 4:03 PM EST - 1 year ago

Sionna Therapeutics Announces Closing of $219.2 million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Feb 6, 2025, 7:51 PM EST - 1 year ago

Sionna Therapeutics Prices Upsized Initial Public Offering

CH_Expat Jul. 24 at 4:50 PM

$SION @Kingjake26 Look here. Dead board. 45 watchers. Look at the MC, look at the IO. I am not invested because I missed it in the low 30s.

1 · Reply

QuietLattice Jul. 24 at 1:06 PM

$SION spiked to ~51 Fri then sold back into the mid-40s. post-spike fade — watching if mid-40s stick

0 · Reply

Soraya123 Jul. 24 at 11:33 AM

0 · Reply

howardlindzon Jul. 19 at 12:59 PM

$SION $ 2 billion just 60 followers - a trend woth literally NO friends

1 · Reply

Trainguy1 Jul. 17 at 8:31 PM

$SION Are we seeing foreshadowing of what’s to happen next week? I wonder if SION will readout top line results from one or two trials?

0 · Reply

laaarsas Jul. 17 at 4:38 PM

$SION FUCK I should have loaded up more in the mid 30s I hate my life.

1 · Reply

STRelativeStrength Jul. 17 at 3:35 PM

$SION undiscovered breakout with 62 watchers

0 · Reply

ajmrtxl Jul. 16 at 1:05 PM

$SION 's latest squeeze play

0 · Reply

laaarsas Jun. 9 at 5:58 AM

$SION Where is next support level?

0 · Reply

laaarsas Jun. 5 at 12:01 PM

$SION No activity here dispite huge gains in last year. What share price do you expect if data is good in Q3?

0 · Reply

laaarsas May. 8 at 12:51 PM

$SION Ok so wow this i quite interesting. Too bad one did not buy a year ago!

0 · Reply

laaarsas May. 6 at 9:33 PM

$SION What dose will we see in phase 2?

0 · Reply

laaarsas May. 6 at 1:12 PM

$SION Why is this stock valued as if the clinical outcome is almost certain?

0 · Reply

laaarsas May. 5 at 7:41 PM

$SION Stock already up much. How much could ph2a data move share price? Tell me

0 · Reply

laaarsas May. 5 at 7:31 PM

$SION Hi donkeys what is vibe in here?

0 · Reply

DARKP00L May. 5 at 1:30 PM

$SION 09:24 on May. 05 2026 Wedbush Initiates Coverage On Sionna Therapeutics with Outperform Rating, Announces Price Target of $53 #tradeideas

2 · Reply

S_Franconi Apr. 21 at 11:18 AM

$SION Very bullish. 59 watchers, April 21, 2026.

0 · Reply

Doozio Apr. 19 at 5:22 PM

$SION appears ready on the DLO ONTO 🐒🍌🧠⏰♾️

0 · Reply

BillionerOfKing Feb. 22 at 2:53 PM

$SION Current Stock Price: $35.52

0 · Reply

Market Cap	2.03B
Revenue (ttm)	0.00
Net Income (ttm)	-75.27M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	654,800
Avg Vol	474,588
Day's Range	N/A - N/A
Shares Out	45.15M
Stochastic %K	24%
Beta	1.33
Analysts	Strong Sell
Price Target	$51.60